Enzyme therapy for functional bowel disease-like post-prandial distress
- PMID: 30101562
- PMCID: PMC6910206
- DOI: 10.1111/1751-2980.12655
Enzyme therapy for functional bowel disease-like post-prandial distress
Abstract
Post-prandial gastrointestinal symptoms such as diarrhea, abdominal distension, flatulence, bloating and a feeling of fullness are common complaints of often unknown etiology and pathogenesis. There is a long history of trials reporting the successful use of products containing a variety of combinations of digestive enzymes including a number of randomized placebo-controlled trials. We provide a narrative review of studies describing the use of multi-digestive enzymes for symptoms consistent with irritable bowel syndrome. We describe clinical trials reported over the past 60 years including double-blinded randomized, placebo-controlled studies and recent trials that focused on post-prandial diarrhea consistent with diarrhea-predominant irritable bowel syndrome. Disaccharidase deficiencies or deficiencies of other carbohydrate digesting enzymes were excluded. Worldwide studies have generally reported success with multi-enzyme preparations although none used a factorial design to identify subgroups or attempted to link specific symptom responses to specific components of therapy. Although there is a long history of the successful use of multi-enzyme preparations for post-prandial symptoms consistent with irritable bowel syndrome, long-term studies using validated scoring systems and factorial designs are needed to confirm the results for specific symptoms and the components of the combination drugs received.
Keywords: diarrhea; digestive enzyme; fecal elastase-1; irritable bowel syndrome; post-prandial distress; therapy.
Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Conflict of interest statement
Conflict of interest
Drs. Ketwaroo and Money have no relevant disclosures.
References
-
- Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67–75.e5. - PubMed
-
- Kellow JE. IBS: do we need to exclude exocrine pancreatic insufficiency in IBS? Nat Rev Gastroenterol Hepatol. 2010;7:479–480. - PubMed
-
- Leeds JS, Hopper AD, Sidhu R, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8:433–438. - PubMed
-
- Money ME, Hofmann AF, Hagey LR, Walkowiak J, Talley NJ. Treatment of irritable bowel syndrome-diarrhea with pancrealipase or colesevelam and association with steatorrhea. Pancreas. 2009;38:232–233. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous